SIGA Technologies shares are powering higher. What’s driving SIGA stock higher?Company Announces Special Cash DividendSiga’s board of directors declared a special cash dividend of $0.60 per share on the company’s common stock. The amount of this dividend is consistent with the special dividend declared last April. This dividend is payable in late April, to shareholders of record at the close of business on April 7.With the major indices red and market breadth weak (only 3 sectors advancing versus 8 declinin ...

At 8:30 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, premarket trading offers a head start in spotting potential breakouts, reversals, or sharp price swings. These early moves often indicate where momentum may carry into the regular session, making premarket analysis a key part of the trading day.In the Green - Premarket GainersThe following stocks are trading highe ...

Earnings Call InsightsSIGA outlines continued TPOXX global expansion and expects EMA smallpox decision in March 2026Mar. 10, 2026 6:10 PM ETSIGA Technologies, Inc. (SIGA) StockAI-Generated Earnings Calls InsightsCommentsEarnings Call Insights: SIGA Technologies (SIGA) Q4 2025 Management View CEO Diem Nguyen noted a continued focus on supporting governments globally in preparedness for biological threats, especially smallpox, with SIGA serving "as the leading provider of smallpox antiviral treatment to more ...

Financial Data and Key Metrics Changes - In 2025, SIGA reported total product revenues of approximately $88 million, which includes $53 million from oral TPOXX and $26 million from IV TPOXX under the BARDA 19C contract, along with $6 million from international oral TPOXX sales [3][10] - The company achieved a pretax operating income of approximately $24 million and a net income of approximately $23 million for 2025, resulting in a fully diluted income per share of $0.32 [10][11] - As of December 31, 2025, SIGA maintained a strong cash position with approximately $155 million in cash and no debt [11] Business Line Data and Key Metrics Changes - The primary revenue driver for SIGA in 2025 was product deliveries to the U.S. Strategic National Stockpile (SNS) under the BARDA contract, which accounted for the majority of product revenues [10] - The company secured $27 million in funding for pediatric formulation development and IV technology transfer efforts, reinforcing the role of TPOXX in biothreat preparedness [4] Market Data and Key Metrics Changes - SIGA received a $13 million order from a country in the Asia-Pacific region, indicating ongoing international engagement and demand for TPOXX [6][21] - The company is actively discussing stockpiling of TPOXX with various potential customers globally, reflecting a strategic focus on enhancing health security [5][6] Company Strategy and Development Direction - SIGA's strategy emphasizes long-term preparedness for biological threats, particularly smallpox, through sustained investment and stockpiling of antiviral treatments [2][4] - The company aims to maintain financial strength while advancing strategic initiatives that support long-term value creation for shareholders [9] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of readiness in the face of heightened geopolitical risks and biological threats, asserting that TPOXX's established safety profile makes it suitable for emergency situations [3] - The company remains engaged with U.S. government officials regarding future procurement contracts, indicating a positive outlook for continued collaboration [4][15] Other Important Information - The European Medicines Agency (EMA) is expected to meet in March to issue a recommendation regarding the marketing authorization of Tecovirimat SIGA, with expectations of a positive benefit-risk balance [7] - SIGA is targeting an FDA submission for the post-exposure prophylaxis program within the next 12 months [8][9] Q&A Session Summary Question: Update on the timing of the next U.S. government RFP for TPOXX - Management indicated that smallpox preparedness remains a focus for the U.S. government, but no specific timing details for the next RFP were available [15][16] Question: Capital allocation priorities looking ahead - Management stated that capital management will remain disciplined and flexible, with no immediate updates on special cash dividends [17] Question: Openness to acquisitions or in-licensing opportunities - Management confirmed that the company is open to pursuing acquisitions or in-licensing opportunities while maintaining a disciplined and strategic approach [18] Question: Details on the recent $13 million TPOXX order - Management noted that the order reflects progress in strengthening relationships with government partners, but specific details about the contract could not be disclosed for security reasons [21][22] Question: Expectations for additional international orders - Management expressed that while additional international sales may occur in 2026, the processes can be complex and time-consuming [24]

Financial Data and Key Metrics Changes - In 2025, SIGA reported product revenues of approximately $88 million, which includes $53 million from oral TPOXX, $26 million from IV TPOXX, and $6 million from international oral TPOXX sales [3][10] - The company achieved a pretax operating income of approximately $24 million and a net income of approximately $23 million for the year [10][11] - The fully diluted income per share for 2025 was $0.32, and the company maintained a strong cash balance of approximately $155 million with no debt [11] Business Line Data and Key Metrics Changes - The primary revenue driver for SIGA in 2025 was product deliveries to the U.S. Strategic National Stockpile (SNS) under the BARDA contract, which accounted for the majority of product revenues [10] - The company secured $27 million in funding to support pediatric formulation development and IV technology transfer efforts, reinforcing the role of TPOXX in biothreat preparedness [4] Market Data and Key Metrics Changes - SIGA has approximately $26 million in outstanding U.S. government orders related to the IV TPOXX procurement order, expected to be delivered in 2026 [4][11] - A recent $13 million order from a country in the Asia-Pacific region indicates ongoing international engagement and demand for TPOXX [6][21] Company Strategy and Development Direction - SIGA remains focused on supporting global governments in preparedness strategies for biological threats, particularly smallpox, and aims to be a leading provider of antiviral treatments [2][3] - The company emphasizes strategic stockpiling as foundational to preparedness and continues discussions with various potential customers globally [6][21] - SIGA is open to pursuing acquisitions or in-licensing opportunities to broaden its pipeline while maintaining a disciplined and strategic approach [18] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of readiness in the face of heightened geopolitical risks and biological threats, asserting that TPOXX's established safety profile makes it suitable for emergency situations [3] - The company expects the European Medicines Agency (EMA) to confirm the positive benefit-risk balance of Tecovirimat SIGA for smallpox treatment, with a recommendation expected in March [7][8] - SIGA entered 2026 from a position of strength, focusing on financial discipline and long-term value creation [9] Other Important Information - The company is actively engaged with the U.S. government and key stakeholders regarding future procurement contracts, indicating ongoing productive discussions [4][15] - SIGA's pricing and manufacturing approach aligns with U.S. government priorities, ensuring the lowest prices for TPOXX as the largest customer [5] Q&A Session Summary Question: Update on the timing of the next U.S. government RFP for TPOXX - Management indicated that smallpox preparedness remains a focus for the U.S. government, but no specific timing details for the next RFP were available [15][16] Question: Capital allocation priorities looking ahead - Management stated that capital management will remain disciplined and flexible, with no immediate updates on special cash dividends [17] Question: Openness to acquisitions or in-licensing opportunities - Management confirmed that the company is open to pursuing acquisitions or in-licensing opportunities while maintaining a strategic focus [18] Question: Details on the recent $13 million TPOXX order - Management noted that the order reflects progress in strengthening relationships with government partners, but specific details about the contract could not be disclosed for security reasons [21][22]

Financial Data and Key Metrics Changes - In 2025, SIGA reported total product revenues of approximately $88 million, which includes $53 million from oral TPOXX, $26 million from IV TPOXX, and $6 million from international oral TPOXX sales [3][9] - The company achieved a pretax operating income of approximately $24 million and a net income of approximately $23 million for the year, resulting in a fully diluted income per share of $0.32 [10] - As of December 31, 2025, SIGA maintained a strong cash position with approximately $155 million in cash and no debt [10] Business Line Data and Key Metrics Changes - The primary revenue driver for SIGA in 2025 was product deliveries to the U.S. Strategic National Stockpile (SNS) under the BARDA contract, which accounted for the majority of product revenues [9] - The company secured $27 million in funding to support pediatric formulation development and IV technology transfer efforts during 2025 [4] Market Data and Key Metrics Changes - SIGA continues to engage with international governments and stakeholders to strengthen health security, with a recent $13 million order from a country in the Asia-Pacific region [5][19] - The company is actively discussing stockpiling of TPOXX with various potential customers globally, reflecting an increased focus on preparedness strategies due to rising biothreat risks [5][20] Company Strategy and Development Direction - SIGA's strategy focuses on supporting global preparedness for biological threats, particularly smallpox, through sustained investment and stockpiling of antiviral treatments [2][4] - The company aims to maintain financial strength while advancing strategic initiatives that support long-term value creation [8] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of readiness in the face of heightened geopolitical risks and biological threats, emphasizing the critical role of TPOXX in emergency situations [3] - The company expects to continue its productive relationship with the U.S. government and anticipates a new procurement contract to further support stockpiling efforts [4][15] Other Important Information - The European Medicines Agency (EMA) is expected to meet in March to issue a recommendation regarding the marketing authorization of Tecovirimat SIGA, with expectations of a positive benefit-risk balance [6] - SIGA is advancing its pediatric program to develop an oral suspension formulation for children, with a phase 1 study recently initiated [8] Q&A Session Summary Question: Update on the timing of the next U.S. government RFP for TPOXX - Management indicated that smallpox preparedness remains a focus for the U.S. government, but no specific timing details for the next RFP were available [14][15] Question: Capital allocation priorities looking ahead - Management stated that capital management will remain disciplined and flexible, with no immediate updates on special cash dividends [16] Question: Openness to acquisitions or in-licensing opportunities - Management confirmed that the company is open to pursuing acquisitions or in-licensing opportunities while maintaining a disciplined and strategic approach [17] Question: Details on the recent $13 million TPOXX order - Management noted that the order is from a repeat customer under a multi-year contract, but specific details could not be disclosed for security reasons [19][20] Question: Expectations for additional international orders - Management expressed that while additional international sales may occur in 2026, the processes can be complex and time-consuming [20]

(Address of principal executive offices) Commission File No. 0-23047 SIGA Technologies, Inc. (Exact name of registrant as specified in its charter) incorporation or organization) 31 East 62nd Street 10065 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) Registrant's telephone number, including area code: (212) 672-9100 Securities registered pursuant to Section 12(b) of the Act: | | | Name of each exchange on which | | --- | --- | --- | | Title of ...

Revenue Performance - SIGA generated $88 million in product revenues for the year 2025, a decrease from $133.3 million in 2024[4] - Total revenues for 2025 were $94.6 million, compared to $138.7 million in 2024[4] - SIGA delivered $53 million of oral TPOXX revenues and $26 million of IV TPOXX revenues in 2025[6] Profitability - The company reported a pre-tax operating income of $24 million in 2025, down from $70 million in 2024[4] - The net loss for 2025 was $5.4 million, compared to a net income of $45.7 million in 2024[4] - Operating expenses increased to $70.9 million in 2025 from $68.7 million in 2024[15] Funding and Contracts - SIGA received a $13 million international procurement order for oral TPOXX in January 2026, part of a multi-year contract[6] - The company secured $27 million in additional U.S. Government funding to support development activities in 2025[2] Future Expectations - The company expects the European Medicine Agency to confirm the positive benefit-risk balance of tecovirimat for smallpox and related indications in March 2026[6] Cash Position - Cash and cash equivalents as of December 31, 2025, were approximately $155 million, slightly down from $155.4 million in 2024[14]

Generated TPOXX Product Revenues of $88 Million in 2025 Received $13 Million International Procurement Order for Oral TPOXX in January 2026  Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2025. “In 2025, we continued to advance SIGA's key long-term priorities, including securing $27 mil ...

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, March 10, 2026. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor ...